The rationale and ethics of medication-free research in schizophrenia

Archives of General Psychiatry

Volumn 54, Issue 5, 1997, Pages 401-407

  Carpenter Jr , William T ^a,d   Schooler, Nina R ^b   Kane, John M ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG WITHDRAWAL; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; MEDICAL RESEARCH; NOTE; PATIENT MONITORING; PSYCHIATRIC TREATMENT; SCHIZOPHRENIA;

EID: 1842301779     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830170015002     Document Type: Note

References (58)

1. Office for Protection From Research Risks, Division of Human Subject Protections. Evaluation of Human Subject Protections in Schizophrenia Research. Los Angeles: University of California, Los Angeles; May 11, 1994.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
3. Meltzer HY. Treatment of the neuroleptic nonresponsive schizophrenic patient. Schizophr Bull. 1992;18:515-542.
4. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151:825-835.
5. Leber P. Is there an alternative to the randomized controlled trial? Psychopharmacol Bull. 1991; 27:3-8.
6. Temple R. Special study designs: early escape, enrichment, studies in non-responders. Community Stat Theory Meth. 1994;23:499-531.
7. Kane JM, Borenstein M. The use of placebo controls in psychiatric research. Presented at the First National Conference on Ethics in Neurobiologic Research With Human Subjects; January 7, 1995; Baltimore, Md.
8. Gilbert PL, Harris J, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 1995; 52:173-188.
9. Wagemaker H Jr, Cade R. The use of hemodialysis in chronic schizophrenia. Am J Psychiatry. 1977; 134:684-685.
10. Schulz SC, van Kammen DP, Balow JE, Flye MW, Bunney WE Jr. Dialysis in schizophrenia: a double-blind evaluation. Science. 1981;211:1066-1068.
11. Carpenter WT, Sadler JH, Light PD, Hanlon TE, Kurland AA, Penna MW, Reed WP, Wilkinson EH, Bartko JJ. The therapeutic efficacy of hemodialysis in schizophrenia. N Engl J Med. 1983;308: 669-675.
12. Wagemaker H, Rogers JL, Cade R. Schizophrenia, hemodialysis, and the placebo effect: results and issues. Arch Gen Psychiatry. 1984;41:805-810.
13. Kane J, Jeste DV, Barnes TRE, Casey DE, Cole JO, Davis JM, Gualtieri CT, Schooler NR, Sprague RL, Wettstein RM. American Psychiatric Association Task Force Report on Tardive Dyskinesia. Washington, DC: American Psychiatric Press; 1992.
14. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994; 331:394-398.
15. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994;151:20-26.
16. Umbricht DSG, Lieberman JA, Kane JM. The clinical efficacy of clozapine in the treatment of schizophrenia. Rev Contemp Pharmacother. 1995;6: 165-186.
17. Carpenter WT, Rey AC, Stephens JM. Further remarks on covert dyskinesia in ambulatory schizophrenia. Lancet. June 19, 1982:1421.
18. Lieberman JA, Lesser M, John C, Pollack S, Saltz B, Kane J. Pharmacologic studies of tardive dyskinesia. J Clin Psychopharmacol. 1988;8(suppl 4): 57-63.
19. Carpenter WT, Tamminga CA. Why neuroleptic withdrawal in schizophrenia? Arch Gen Psychiatry. 1995;52:192-193.
20. Caldwell AE. Origins of Psychopharmacology: From CPZ to LSD. Springfield, Ill: Charles C Thomas Publisher; 1970.
21. Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry. 1995;52:189-192.
22. Greden JF, Tandon R. Long-term treatment for lifetime disorders? Arch Gen Psychiatry. 1995; 52:197-200.
23. Meltzer HY. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry. 1995;52: 200-202.
24. Nuechterlein KH, Gitlin MJ, Subotnik KL. The early course of schizophrenia and long-term maintenance neuroleptic therapy. Arch Gen Psychiatry. 1995;52:203-205.
25. Wyatt RJ. The risks of withdrawing antipsychotic medications. Arch Gen Psychiatry. 1995;52:205-208.
26. Jeste DV, Gilbert PL, McAdams LA, Harris MJ. Considering neuroleptic maintenance and taper on a continuum. Arch Gen Psychiatry. 1995;52:209-212.
27. Proceedings From the First National Conference on Ethics in Neurobiological Research With Human Subjects. Baltimore Marriott Inner Harbor, January 7-9, 1995; Baltimore, Md. Discussions.
28. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17:235-280.
29. Gariano RF, Young SJ, Jeste DV, Segal DS, Groves PM. Effects of long-term administration of haloperidol on electrophysiologic properties of rat mesencephalic neurons. J Pharmacol Exp Ther. 1990; 255:108-113.
30. Benes FM, Paskevich PA, Domesick VB. Haloperidol-induced plasticity of axon terminals in rat substantia nigra. Science. 1983;221:969-971.
31. Meshul CK, Casey DE. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res. 1989;489:338-346.
32. Roberts RC, Gaither LA, Gao XM, Kashyap SM, Tamminga CA. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum. Synapse. 1995;20:234-243.
33. May PRA. Treatment of Schizophrenia: A Comparative Study of Five Treatment Methods. New York, NY: Science House; 1968.
34. May PRA, Tuma AH, Dixon WJ. Schizophrenia: a follow-up study of results of five forms of treatment. Arch Gen Psychiatry. 1981;38:776-784.
35. Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Havez H, Mirza M, Vana J. Intermittent vs maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry. 1991; 48:333-339.
36. Carpenter WT Jr, Heinrichs DW, Hanlon TE. A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry. 1987;144:1466-1470.
37. Carpenter WT Jr, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, Buchanan RW. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry. 1990;147:1138-1148.
38. Schooler NR. Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr Bull. 1991;17:311-324.
39. Schooler NR, Keith SJ, Severe JB, Matthews SM. Treatment strategies in schizophrenia: effects of dosage reduction and family management on outcome. Schizophr Res. 1993;9:260. Abstract.
40. Kreisman D, Blumenthal R, Borenstein M, Woemer M, Kane JM, Rifkin A, Reardon G. Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: the family's view. Psychiatry. 1988;51:3-13.
41. Curson DA, Hirsch SR, Platt SD, Bamber RW, Barnes TRE. Does short term placebo treatment of chronic schizophrenia produce long term harm? BMJ. 1986;293:726-728.
42. Bellack AS, Mueser KT. Psychosocial treatment for schizophrenia. Schizophr Bull. 1993;19:317-336.
43. Carpenter WT, Heinrichs DW. Early intervention, time-limited targeted pharmacotherapy in schizophrenia. Schizophr Bull. 1983;9:533-542.
44. Pietzcker A, Gaebel W, Kopcke W, Linden M, Muller P, Muller-Spahn F, Tegeler J. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia: 2 year results of a German multicenter study. J Psychiatr Res. 1993;27:321-339.
45. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull. 1993;19: 287-302.
46. Appelbaum P, Lidz C, Meisel A. Informed Consent - Legal Theory and Clinical Practise. Oxford, England: Oxford University Press; 1987.
47. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. Washington, DC: Dept of Health, Education, and Welfare; 1978.
48. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Summing Up. Washington, DC: Government Printing Office; 1983.
49. Grisso T, Applebaum PS. The MacArthur Treatment Competence Study, III: abilities of patients to consent to psychiatric and medical treatments. Law Human Behav. 1995;19:149-174.
50. Carpenter WT. A new setting for informed consent. Lancet. March 23, 1974:500-501.
51. Katz J. Human experimentation and human rights. St Louis University Law J. 1993;38:7-54.
52. Katz J. Respecting autonomy. In: The Silent World of Doctor and Patient. New York, NY: Free Press; 1984:130-164.
53. Cardon PV, Dommel FW, Trumble RR. Injuries to research subjects: a survey of investigators. N Engl J Med. 1976;95:650-654.
54. Carroll RS, Miller A, Ross B, Simpson GM. Research as an impetus to improved treatment. Arch Gen Psychiatry. 1980;37:377-380.
55. Giller E, Strauss J. Clinical research: a key to clinical training. Am J Psychiatry. 1984;141:1075-1077.
56. Kalman TP, Talon NS, Frances A, Kocsis JH. A controlled study of satisfaction among psychobiology research patients. Am J Psychiatry. 1982; 139:344-347.
57. Kocsis JH, Frances A, Kalman TP, Shear MK. The effect of psychobiological research on treatment outcome: a controlled study. Arch Gen Psychiatry. 1981;38:511-515.
58. Love R, Conley RR. Obtaining informed consent from psychiatrically impaired subjects. Psychiatr Serv. In press.